Share this video  

ESMO 2019 | OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma

Georgina Long, MD, PhD, FRACP, from the University of Sydney, Sydney, Australia, explains the 18-month relapse-free survival and biomarker analyses from the OpACIN-neo trial (NCT02977052). This trial aims to identify the optimal dosing schedule of neoadjuvant ipilimumab and nivolumab in stage III melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.